There is growing awareness of primary aldosteronism as a cause of secondary hypertension. Usually, it manifests as hypertension and hypokalemia, or as resistant hypertension. Much less often, primary aldosteronism may be detected after a hypertensive emergency has developed. We highlight this association by reporting on eight patients with a clinical diagnosis of primary aldosteronism whose course was complicated by a hypertensive crisis. In all patients, an elevated serum aldosterone was accompanied by a suppressed plasma renin activity despite the presence of a hypertensive crisis. A good outcome was obtained either with laparoscopic adrenalectomy (1 patient) or with an antihypertensive drug regimen that included an antialdosterone agent (7 patients). The differential diagnosis of hypertensive emergencies should include primary aldosteronism. Am
J
erome Conn, in 1955, 1 first described primary aldosteronism (PA) as hypertension with hypokalemia due to an aldosterone-producing adrenal adenoma. Initial studies to look for this entity in hypertensive patients concluded that this form of hypertension was rare. Despite this early finding, it is now believed that PA may be as rare as initially thought. 2, 3 Although the exact reasons for this are unclear, it is likely that this is partly because hypertensive patients with normal serum potassium levels are being screened and tested and also due to the increased use of the aldosterone concentration (AC) to plasma renin activity (PRA) ratio (ARR) for screening. 4, 5 In addition to the increased detection of PA, it also appears to have a broader clinical presentation than originally believed. Historically, the clinical presentation of PA is mild-to-moderate hypertension that may be resistant to treatment. More recently, PA has been associated with higher blood pressure (BP) elevations. 6 The description of severe or emergent hypertension with acute target organ damage (hypertensive emergency) in PA has received less attention and the number of case reports to date is limited. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] We describe eight clinical cases of PA (3 confirmed; 5 probable) associated with hypertensive emergencies seen by our Hypertension Consultation Service and illustrate some difficulties in pursuing definitive diagnostic testing is this subgroup with PA.
Methods
All eight patients were evaluated between 1993 and 2004 for acute hypertensive emergency. In all cases, other forms of secondary hypertension were excluded based on clinical and radiologic testing. A definite diagnosis of PA was made if urinary AC was Ͼ12 g/d and urinary sodium (Na ϩ ) Ͼ200 mEq/d. 22 Probable PA was assumed if AC was Ͼ15 ng/dL and ARR was Ͼ40, but no diagnostic sodium suppression was performed or if results were indeterminate. Subtype determination was initially done with computerized tomography (CT) scan and adrenal vein sampling when possible. Adrenal vein sampling was typically done under cosyntropin stimulation according to the Doppman method. 23 The adrenal venous aldosteroneto-cortisol ratio on the affected side had to be at least five times higher than on the contralateral side 23 for the patient to be considered for surgery.
Laboratory reference ranges include potassium (K ϩ ) of 3.5 to 5.0 mEq/L and serum creatinine (SCr) of 0.6 to 1.2 mg/dL in all patients. Upright PRA ranges for all cases (1.0 to 9.0 ng/mL/h). 
Discussion
This case series (Table 1) illustrates that patients with clinical primary aldosteronism can have severe hypertension and develop hypertensive emergencies. It also illustrates some of the difficulties in the confirmatory testing and diagnosis of PA in the setting of acute hypertensive crisis when sodium loading may not be safe. All of our patients had elevated AC and suppressed PRA despite having a hypertensive emergency and antialdosterone treatment was quite effective in lowering BP. Of our eight hypertensive emergency cases, three had confirmed primary aldosteronism (diagnostic sodium loading tests) and five were deemed probable cases based on their elevated ARR and excellent responses to antialdosterone blockade (sodium loading considered unsafe or indeterminate). Of the five "probable" cases, two had elevated urinary aldosterone levels but urinary sodium was not sufficient (Ͼ200 mEq/24 h) to establish the diagnosis. The remaining three cases did not have confirmatory testing performed because of their clinical status. The mean ARR for the confirmed and probable cases were 119 and 117, respectively. Hypertensive encephalopathy was a concomitant diagnosis in five cases and congestive heart failure was present in three cases. The average time between initial diagnosis of hypertension and subsequent diagnosis of primary aldosteronism was 15.6 years.
The diagnosis of PA in our "probable" cases can be debated. A critical observer may label these cases as low renin hypertension because we did not complete definitive sodium loading. We used a random AC of 15 ng/dL as one criterion for a positive screening test but this is more sensitive in a sodium loaded state. However, in the acutely ill patients such as ours, it is impractical to do sodium loading. Our second criterion for a positive screening test was an elevated ARR of more than 40. Although the optimal ratio for a positive test is debated, a AC/PRA ratio Ն20 to 30 and a AC Ն15 after sodium loading provides excellent sensitivity in screening. 24 The PRA has a profound effect on the ARR and small changes may lead to false-positive screening tests. Despite these limitations we believe our probable cases actually have PA.
The BP-lowering effects observed in our patients with aldosterone blockade have also been reported in patients with refractory hypertension with and without PA. Nishizaka et al 25 reported that the addition of low doses of spironolactone to a multidrug regimen in patients with resistant hypertension led to a marked decline in BP and allowed reduction of other medications. Furthermore, the benefit was seen in patients with and without a diagnosis of PA. Likewise Ouzan et al 26 reported a marked benefit in BP for 25 patients with essential hypertension who had spironolactone added at a dose of 1 mg/kg/d. It should be noted, however, that hypertensive crises are associated at times with secondary hyperaldosteronism and in that setting aldosterone blockade may be less useful.
Primary aldosteronism should obviously be suspected in patients with hypertension and hypokalemia, resistant hypertension, and hypertension associated with adrenal masses. It should also be considered as shown by our cases in the setting of a hypertensive emergency. Traditional diagnostic sodium loading may be difficult in this group of patients.
